Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers

An Open-Label, Randomized, 3-Way Crossover, Single-Dose Study in Healthy Volunteers Comparing the Bioavailability of CMX001 (HDP-Cidofovir Conjugate) Delivered as a Tablet Formulation vs a Solution Formulation and the Effect of Food on CMX001 Bioavailability

The purpose of this study is to compare the bioavailability of CMX001 when administered as a tablet vs a solution and to determine the effect of a high-fat meal on CMX001 bioavailability.

Inclusion Criteria:

• Healthy males and non-childbearing females 18-55 years old

Exclusion Criteria:

• Use of an investigational drug and/or treatment within 30 days prior to enrollment.
• Positive HIV, Hepatitis B or Hepatitis C test result
• Tobacco user
• History of GI disease or disorder
• History of positive fecal occult blood test (FOBT)
• Body Mass Index (BMI) > 30 or < 18, or body weight < 50 kg
• Prior abdominal or pelvic surgery